Rock Springs Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Rock Springs Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-203,817	Closed	-$14.9M	–	163
2020 Q2	$14.9M	Buy	203,817 +3,817	+2%	+$203K	0.41%	82
2020 Q1	$6.81M	Hold	200,000	–	–	0.28%	89
2019 Q4	$10.9M	Sell	200,000 -143,500	-42%	-$7.11M	0.34%	83
2019 Q3	$14.3M	Hold	343,500	–	–	0.57%	59
2019 Q2	$15M	Buy	343,500 +83,500	+32%	+$4.71M	0.54%	66
2019 Q1	$13.4M	Hold	260,000	–	–	0.52%	65
2018 Q4	$9.62M	Hold	260,000	–	–	0.45%	72
2018 Q3	$9.76M	Sell	260,000 -137,500	-35%	-$5.06M	0.35%	87
2018 Q2	$15.7M	Buy	397,500 +72,500	+22%	+$2.3M	0.6%	61
2018 Q1	$8.37M	Buy	325,000 +81,000	+33%	+$2.42M	0.36%	89
2017 Q4	$6.58M	Hold	244,000	–	–	0.3%	92
2017 Q3	$9.12M	Sell	244,000 -63,000	-21%	-$1.91M	0.42%	76
2017 Q2	$7.67M	Buy	+307,000	New	+$7.07M	0.39%	79

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rock Springs Capital Management's BHVN Position: Q3 2020 in Review

Rock Springs Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2020, closing a stake of 203,817 shares — an estimated $14.9M sold.

Rock Springs Capital Management first reported a position in BHVN in Q2 2017 and held it in 13 quarters. The position peaked at $15.7M in Q2 2018. 215 funds tracked by Wall St. Rank hold BHVN as of Q3 2020.

Rock Springs Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2020 after selling out during the quarter.
Rock Springs Capital Management sold 203,817 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2020, an estimated $14.9M.
Rock Springs Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 13 quarters.
Rock Springs Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $15.7M in Q2 2018.
215 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2020.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.